This Review provides an overview of the existing mechanistic insights into compromised vaccine response for respiratory infectious diseases in older people, defined as aged 65 years and older, ...
The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access
A protein-based maternal vaccine and monoclonal antibody (mAb) are now market-approved to protect infants, while an mRNA and two protein-based vaccines are approved for older adults. First-year ...
Aussies who are classified as 'moderate to high risk' and are aged between 18 and 64 now qualify for the immunisation.
About one in three people will develop shingles in their lifetime and nearly all adults aged 50 years and older carry the inactive virus that causes it. But the the risk of develo ...
Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...
Additionally, Dr. Brangman says that the Tdap vaccine, which protects against tetanus, diphtheria and whooping cough, is also ...
Rhode Island has the highest vaccination rate across the country, while Mississippi was found to have the lowest, a new study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback